SCHEMBL6133795

SCHEMBL6133795

Cc1cccc(NC(=O)N(C)c2nc(-c3ccccc3)c(-c3ccc(=O)n(C(C)C)n3)s2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.42
MAPT P10636 4/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.37
TP53 P04637 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
FAAH O00519 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KCNJ6 P48051 1/20 0.36
KCNJ5 P48544 1/20 0.36
KCNJ3 P48549 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
PPARG P37231 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133768 0.84 KCNJ6 (0.46) NPSR1MAPTALDH1A1LMNAKDM4E
SCHEMBL6133209 0.82 TP53 (0.39) MAPTALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL6134884 0.79 ALDH1A1 (0.40) MAPTALDH1A1LMNAKDM4ETP53
SCHEMBL6133216 0.78 ADORA2A (0.51) NPSR1MAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL6133228 0.78 XIAP (0.48) MAPTALDH1A1TP53MEN1KMT2A
SCHEMBL6828866 0.77 NPSR1 (0.42) NPSR1MAPTALDH1A1LMNAKDM4E
SCHEMBL6133645 0.73 TP53 (0.38) MAPTALDH1A1KDM4ESMN1; SMN2TP53
SCHEMBL6133654 0.73 ALDH1A1 (0.54) MAPTALDH1A1LMNAKDM4ETP53
SCHEMBL6133608 0.73 MEN1 (0.48) NPSR1MAPTALDH1A1LMNAKDM4E
SCHEMBL6135469 0.73 XIAP (0.55) MAPTALDH1A1LMNASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof MC2R, CYP2C9, OXTR NPSR1 432/4885MAPT 3008/4885ALDH1A1 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.